Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Phase 1 Completed 14 enrolled St. Jude Children's Research Hospital Assisi Foundation · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).

Timeline

Start: 2009-10
Primary completion: 2013-05
Completion: 2014-05

Publications

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	genetically modified NK cells	Cell therapy	—	—

Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Summary

Timeline

Publications

Drugs

Indications